To get a sense of who is truly in control of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), it is important to understand the ownership structure of the business. We can see that institutions own the ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Equities research analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Arrowhead ...

US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals’ New Drug Application for investigational plozasiran for familial chylomicronemia syndrome, a severe and rare ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...